Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01358695 · ClinicalTrials.gov registry record · Phase 2

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

A Phase 2 study, sponsored by Anterios.

Completed
Registry status
Phase 2
Development phase
111
Enrollment target

NCT01358695 is a Phase 2 study that has completed, run by Anterios. The registered enrollment target is 111 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01358695, a Phase 2 study, has completed, sponsored by Anterios.

COMPLETED
Registry status
Phase 2
Development phase
111 participants
Enrollment target

Study Summary

The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.

Interventions

  • BIOLOGICAL Botulinum Toxin Type A
  • BIOLOGICAL ANT-1207
  • BIOLOGICAL Botulinum Toxin, Type A

Trial Details

FieldValue
Enrollment Target 111 participants
Start Date 2011-05
Est. Completion 2012-05
Phase Phase 2

Sponsor

Anterios

5 total trials

What the Registry Record Tells You About NCT01358695

The ClinicalTrials.gov registry entry for NCT01358695 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 111 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anterios, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Botulinum Toxin Type A is the first listed.

NCT01358695 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01358695 about?

NCT01358695 is a clinical study titled "Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet". The purpose of this study is to provide evidence of the safety, tolerance, and efficacy of ANT-1207 in the treatment of Crow's Feet.

What is the current status of trial NCT01358695?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 111 participants. The study started on 2011-05. Estimated completion is 2012-05.

What interventions are being tested in trial NCT01358695?

The interventions under investigation include: Botulinum Toxin Type A (BIOLOGICAL), ANT-1207 (BIOLOGICAL), Botulinum Toxin, Type A (BIOLOGICAL).

Who is sponsoring clinical trial NCT01358695?

This trial is sponsored by Anterios, which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.